{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T11:27:44Z","timestamp":1793014064082,"version":"4.5.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-84606-7","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T15:59:02Z","timestamp":1743263942000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Subsequent primary cancer risk and mortality among premenopausal breast cancer survivors"],"prefix":"10.1038","volume":"15","author":[{"given":"Mei","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihuai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianbo","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunfu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xihu","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,28]]},"reference":[{"issue":"1","key":"84606_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. CA Cancer J. Clin. 73 (1), 17\u201348 (2023).","journal-title":"CA Cancer J. Clin."},{"issue":"5","key":"84606_CR2","doi-asserted-by":"publisher","first-page":"409","DOI":"10.3322\/caac.21731","volume":"72","author":"KD Miller","year":"2022","unstructured":"Miller, K. D. et al. Cancer treatment and survivorship statistics, 2022. CA Cancer J. Clin. 72 (5), 409\u2013436 (2022).","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"84606_CR3","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3322\/caac.21319","volume":"66","author":"CD Runowicz","year":"2016","unstructured":"Runowicz, C. D. et al. American Cancer Society\/American Society of clinical oncology breast Cancer Survivorship Care Guideline. CA Cancer J. Clin. 66 (1), 43\u201373 (2016).","journal-title":"CA Cancer J. Clin."},{"issue":"10","key":"84606_CR4","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/S1470-2045(08)70256-0","volume":"9","author":"CL Loprinzi","year":"2008","unstructured":"Loprinzi, C. L., Wolf, S. L., Barton, D. L. & Laack, N. N. Symptom management in premenopausal patients with breast cancer. Lancet Oncol. 9 (10), 993\u20131001 (2008).","journal-title":"Lancet Oncol."},{"issue":"6","key":"84606_CR5","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/S1470-2045(13)70076-7","volume":"14","author":"T DiSipio","year":"2013","unstructured":"DiSipio, T., Rye, S., Newman, B. & Hayes, S. Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. Lancet Oncol. 14 (6), 500\u2013515 (2013).","journal-title":"Lancet Oncol."},{"issue":"4","key":"84606_CR6","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1093\/eurheartj\/ehab745","volume":"43","author":"A Guha","year":"2022","unstructured":"Guha, A. et al. Incidence, risk factors, and mortality of atrial fibrillation in breast cancer: a SEER-Medicare analysis. Eur. Heart J. 43 (4), 300\u2013312 (2022).","journal-title":"Eur. Heart J."},{"issue":"15","key":"84606_CR7","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1200\/JCO.21.01736","volume":"40","author":"H Greenlee","year":"2022","unstructured":"Greenlee, H. et al. Risk of Cardiovascular Disease in Women with and without breast Cancer: the pathways Heart Study. J. Clin. Oncol. 40 (15), 1647\u20131658 (2022).","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"84606_CR8","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa1209825","volume":"368","author":"SC Darby","year":"2013","unstructured":"Darby, S. C. et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl. J. Med. 368 (11), 987\u2013998 (2013).","journal-title":"N Engl. J. Med."},{"issue":"9","key":"84606_CR9","doi-asserted-by":"publisher","first-page":"e1911838","DOI":"10.1001\/jamanetworkopen.2019.11838","volume":"2","author":"H Abdel-Qadir","year":"2019","unstructured":"Abdel-Qadir, H. et al. Association of early-stage breast Cancer and subsequent chemotherapy with risk of Atrial Fibrillation. JAMA Netw. Open. 2 (9), e1911838 (2019).","journal-title":"JAMA Netw. Open."},{"issue":"3","key":"84606_CR10","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3322\/caac.20103","volume":"61","author":"A VanderWalde","year":"2011","unstructured":"VanderWalde, A. & Hurria, A. Aging and osteoporosis in breast and prostate cancer. CA Cancer J. Clin. 61 (3), 139\u2013156 (2011).","journal-title":"CA Cancer J. Clin."},{"key":"84606_CR11","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ctrv.2016.11.012","volume":"52","author":"RA Leon-Ferre","year":"2017","unstructured":"Leon-Ferre, R. A., Majithia, N. & Loprinzi, C. L. Management of hot flashes in women with breast cancer receiving ovarian function suppression. Cancer Treat. Rev. 52, 82\u201390 (2017).","journal-title":"Cancer Treat. Rev."},{"issue":"5","key":"84606_CR12","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1200\/JCO.19.00126","volume":"38","author":"HA Kim","year":"2020","unstructured":"Kim, H. A. et al. Adding ovarian suppression to tamoxifen for premenopausal breast Cancer: a Randomized Phase III Trial. J. Clin. Oncol. 38 (5), 434\u2013443 (2020).","journal-title":"J. Clin. Oncol."},{"issue":"19","key":"84606_CR13","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1200\/JCO.2018.78.1914","volume":"36","author":"K Oktay","year":"2018","unstructured":"Oktay, K. et al. Fertility preservation in patients with Cancer: ASCO Clinical Practice Guideline Update. J. Clin. Oncol. 36 (19), 1994\u20132001 (2018).","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"84606_CR14","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1200\/JCO.2017.75.8995","volume":"36","author":"J Carter","year":"2018","unstructured":"Carter, J. et al. Interventions to address sexual problems in people with Cancer: American Society of Clinical Oncology Clinical Practice Guideline Adaptation of Cancer Care Ontario Guideline. J. Clin. Oncol. 36 (5), 492\u2013511 (2018).","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"84606_CR15","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s10549-020-06067-6","volume":"187","author":"AM Williams","year":"2021","unstructured":"Williams, A. M. et al. Fatigue, anxiety, and quality of life in breast cancer patients compared to non-cancer controls: a nationwide longitudinal analysis. Breast Cancer Res. Treat. 187 (1), 275\u2013285 (2021).","journal-title":"Breast Cancer Res. Treat."},{"issue":"7","key":"84606_CR16","doi-asserted-by":"publisher","first-page":"e28385","DOI":"10.1016\/j.heliyon.2024.e28385","volume":"10","author":"FM Schipilliti","year":"2024","unstructured":"Schipilliti, F. M. et al. Datopotamab deruxtecan: a novel antibody drug conjugate for triple-negative breast cancer. Heliyon 10 (7), e28385 (2024).","journal-title":"Heliyon"},{"key":"84606_CR17","doi-asserted-by":"publisher","first-page":"1362641","DOI":"10.3389\/fonc.2024.1362641","volume":"14","author":"R Caputo","year":"2024","unstructured":"Caputo, R. et al. Sacituzumab Govitecan for the treatment of advanced triple negative breast cancer patients: a multi-center real-world analysis. Front. Oncol. 14, 1362641 (2024).","journal-title":"Front. Oncol."},{"issue":"12","key":"84606_CR18","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1007\/s00520-023-08083-w","volume":"31","author":"DC Guven","year":"2023","unstructured":"Guven, D. C. et al. Immune checkpoint inhibitor-related hearing loss: a systematic review and analysis of individual patient data. Support Care Cancer. 31 (12), 624 (2023).","journal-title":"Support Care Cancer"},{"issue":"18","key":"84606_CR19","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.2217\/fon-2021-1647","volume":"18","author":"A Rizzo","year":"2022","unstructured":"Rizzo, A. et al. KEYNOTE-522, IMpassion031 and GeparNUEVO: changing the paradigm of neoadjuvant immune checkpoint inhibitors in early triple-negative breast cancer. Future Oncol. 18 (18), 2301\u20132309 (2022).","journal-title":"Future Oncol."},{"issue":"10","key":"84606_CR20","doi-asserted-by":"publisher","first-page":"755","DOI":"10.2217\/imt-2022-0021","volume":"14","author":"A Rizzo","year":"2022","unstructured":"Rizzo, A. & Palmiotti, G. Neoadjuvant chemoimmunotherapy in early triple-negative breast cancer: a new kid on the block? Immunotherapy 14 (10), 755\u2013758 (2022).","journal-title":"Immunotherapy"},{"issue":"12","key":"84606_CR21","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1080\/17425255.2021.2029405","volume":"17","author":"A Rizzo","year":"2021","unstructured":"Rizzo, A. et al. Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study. Expert Opin. Drug Metab. Toxicol. 17 (12), 1455\u20131466 (2021).","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"84606_CR22","doi-asserted-by":"crossref","unstructured":"Sahin, T. K., Rizzo, A., Aksoy, S. & Guven, D. C. Prognostic significance of the Royal Marsden Hospital (RMH) score in patients with Cancer: a systematic review and Meta-analysis. Cancers (Basel) 16(10), 1835 (2024).","DOI":"10.3390\/cancers16101835"},{"key":"84606_CR23","doi-asserted-by":"crossref","unstructured":"Vitale, E., Rizzo, A., Santa, K. & Jirillo, E. Associations between Cancer Risk, inflammation and metabolic syndrome: a scoping review. Biology (Basel) 13(5), 352 (2024).","DOI":"10.3390\/biology13050352"},{"key":"84606_CR24","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ejca.2022.09.031","volume":"177","author":"G Viscardi","year":"2022","unstructured":"Viscardi, G. et al. Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis. Eur. J. Cancer. 177, 175\u2013185 (2022).","journal-title":"Eur. J. Cancer"},{"issue":"4","key":"84606_CR25","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/S1470-2045(18)30903-3","volume":"20","author":"CJ Bright","year":"2019","unstructured":"Bright, C. J. et al. Risk of subsequent primary neoplasms in survivors of adolescent and young adult cancer (teenage and young adult Cancer Survivor Study): a population-based, cohort study. Lancet Oncol. 20 (4), 531\u2013545 (2019).","journal-title":"Lancet Oncol."},{"issue":"8","key":"84606_CR26","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1093\/jnci\/djac091","volume":"114","author":"H Sung","year":"2022","unstructured":"Sung, H. et al. Subsequent primary Cancer risk among 5-Year survivors of adolescent and young adult cancers. J. Natl. Cancer Inst. 114 (8), 1095\u20131108 (2022).","journal-title":"J. Natl. Cancer Inst."},{"issue":"24","key":"84606_CR27","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1001\/jama.2020.23130","volume":"324","author":"H Sung","year":"2020","unstructured":"Sung, H., Hyun, N., Leach, C. R., Yabroff, K. R. & Jemal, A. Association of First Primary Cancer with risk of subsequent primary Cancer among survivors of adult-onset cancers in the United States. Jama 324 (24), 2521\u20132535 (2020).","journal-title":"Jama"},{"key":"84606_CR28","unstructured":"NCCN Clinical Practice Guidelines in Oncology, Breast Cancer, Version 4. [ (2023). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf]"},{"key":"84606_CR29","unstructured":"Multiple Primary and Histology Coding Rules [ (2007). https:\/\/seer.cancer.gov\/tools\/mphrules\/]"},{"key":"84606_CR30","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1742-5573-5-7","volume":"5","author":"K Rostgaard","year":"2008","unstructured":"Rostgaard, K. Methods for stratification of person-time and events - a prerequisite for Poisson regression and SIR estimation. Epidemiol. Perspect. Innov. 5, 7 (2008).","journal-title":"Epidemiol. Perspect. Innov."},{"issue":"11","key":"84606_CR31","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1093\/aje\/kwg278","volume":"158","author":"Y Yasui","year":"2003","unstructured":"Yasui, Y. et al. A methodological issue in the analysis of second-primary cancer incidence in long-term survivors of childhood cancers. Am. J. Epidemiol. 158 (11), 1108\u20131113 (2003).","journal-title":"Am. J. Epidemiol."},{"key":"84606_CR32","unstructured":"New Malignancies Among Cancer Survivors. SEER Cancer Registries, 1973\u20132000 [https:\/\/seer.cancer.gov\/archive\/publications\/mpmono\/MPMonograph_complete.pdf]"},{"issue":"11","key":"84606_CR33","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1016\/S1470-2045(22)00561-7","volume":"23","author":"LHS Veiga","year":"2022","unstructured":"Veiga, L. H. S. et al. Treatment-related thoracic soft tissue sarcomas in US breast cancer survivors: a retrospective cohort study. Lancet Oncol. 23 (11), 1451\u20131464 (2022).","journal-title":"Lancet Oncol."},{"issue":"9","key":"84606_CR34","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1008862","volume":"364","author":"S Rao Kondapally Seshasai","year":"2011","unstructured":"Rao Kondapally Seshasai, S. et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl. J. Med. 364 (9), 829\u2013841 (2011).","journal-title":"N Engl. J. Med."},{"issue":"2","key":"84606_CR35","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1703643","volume":"377","author":"G von Minckwitz","year":"2017","unstructured":"von Minckwitz, G. et al. Adjuvant pertuzumab and trastuzumab in early HER2-Positive breast Cancer. N Engl. J. Med. 377 (2), 122\u2013131 (2017).","journal-title":"N Engl. J. Med."},{"issue":"26","key":"84606_CR36","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1056\/NEJM199206253262605","volume":"326","author":"RE Curtis","year":"1992","unstructured":"Curtis, R. E. et al. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N. Engl. J. Med. 326 (26), 1745\u20131751 (1992).","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"84606_CR37","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1200\/JCO.2003.03.114","volume":"21","author":"RE Smith","year":"2003","unstructured":"Smith, R. E., Bryant, J., DeCillis, A. & Anderson, S. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical adjuvant breast and Bowel Project experience. J. Clin. Oncology: Official J. Am. Soc. Clin. Oncol. 21 (7), 1195\u20131204 (2003).","journal-title":"J. Clin. Oncology: Official J. Am. Soc. Clin. Oncol."},{"issue":"18","key":"84606_CR38","doi-asserted-by":"publisher","first-page":"4179","DOI":"10.1200\/JCO.2005.05.029","volume":"23","author":"C Praga","year":"2005","unstructured":"Praga, C. et al. Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide. J. Clin. Oncology: Official J. Am. Soc. Clin. Oncol. 23 (18), 4179\u20134191 (2005).","journal-title":"J. Clin. Oncology: Official J. Am. Soc. Clin. Oncol."},{"issue":"3","key":"84606_CR39","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1200\/JCO.2006.05.9048","volume":"25","author":"MC Le Deley","year":"2007","unstructured":"Le Deley, M. C. et al. Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer. J. Clin. Oncol. 25 (3), 292\u2013300 (2007).","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"84606_CR40","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1200\/JCO.2013.54.6119","volume":"33","author":"AC Wolff","year":"2015","unstructured":"Wolff, A. C. et al. Risk of marrow neoplasms after adjuvant breast cancer therapy: the national comprehensive cancer network experience. J. Clin. Oncol. 33 (4), 340\u2013348 (2015).","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"84606_CR41","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1016\/j.jtho.2021.07.001","volume":"16","author":"Y Wang","year":"2021","unstructured":"Wang, Y., Li, J., Chang, S., Dong, Y. & Che, G. Risk and influencing factors for subsequent primary Lung Cancer after treatment of breast Cancer: a systematic review and two Meta-analyses based on four million cases. J. Thorac. Oncol. 16 (11), 1893\u20131908 (2021).","journal-title":"J. Thorac. Oncol."},{"issue":"5","key":"84606_CR42","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.jtho.2017.01.021","volume":"12","author":"YJ Huang","year":"2017","unstructured":"Huang, Y. J. et al. Radiation Therapy for invasive breast Cancer increases the risk of second primary lung Cancer: a Nationwide Population-based cohort analysis. J. Thorac. Oncol. 12 (5), 782\u2013790 (2017).","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"84606_CR43","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1200\/JCO.2007.13.3033","volume":"26","author":"EL Kaufman","year":"2008","unstructured":"Kaufman, E. L., Jacobson, J. S., Hershman, D. L., Desai, M. & Neugut, A. I. Effect of breast cancer radiotherapy and cigarette smoking on risk of second primary lung cancer. J. Clin. Oncol. 26 (3), 392\u2013398 (2008).","journal-title":"J. Clin. Oncol."},{"issue":"18","key":"84606_CR44","doi-asserted-by":"publisher","first-page":"3201","DOI":"10.1158\/0008-5472.CAN-21-4461","volume":"82","author":"F Chen","year":"2022","unstructured":"Chen, F. et al. Genetic risk of second primary Cancer in breast Cancer survivors: the multiethnic cohort study. Cancer Res. 82 (18), 3201\u20133208 (2022).","journal-title":"Cancer Res."},{"issue":"15","key":"84606_CR45","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1200\/JCO.18.01854","volume":"37","author":"AW Kurian","year":"2019","unstructured":"Kurian, A. W. et al. Genetic testing and results in a Population-based cohort of breast Cancer patients and ovarian Cancer patients. J. Clin. Oncology: Official J. Am. Soc. Clin. Oncol. 37 (15), 1305\u20131315 (2019).","journal-title":"J. Clin. Oncology: Official J. Am. Soc. Clin. Oncol."},{"issue":"1","key":"84606_CR46","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12916-022-02260-0","volume":"20","author":"KA Hirko","year":"2022","unstructured":"Hirko, K. A. et al. The impact of race and ethnicity in breast cancer-disparities and implications for precision oncology. BMC Med. 20 (1), 72 (2022).","journal-title":"BMC Med."},{"issue":"2","key":"84606_CR47","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S1470-2045(17)30891-4","volume":"19","author":"ER Copson","year":"2018","unstructured":"Copson, E. R. et al. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. Lancet Oncol. 19 (2), 169\u2013180 (2018).","journal-title":"Lancet Oncol."},{"issue":"5","key":"84606_CR48","doi-asserted-by":"publisher","first-page":"e429","DOI":"10.1016\/j.whi.2012.06.004","volume":"22","author":"SI Mishra","year":"2012","unstructured":"Mishra, S. I., DeForge, B., Barnet, B., Ntiri, S. & Grant, L. Social determinants of breast cancer screening in urban primary care practices: a community-engaged formative study. Womens Health Issues. 22 (5), e429\u2013438 (2012).","journal-title":"Womens Health Issues"},{"issue":"4","key":"84606_CR49","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/hel.12199","volume":"20","author":"T Nguyen","year":"2015","unstructured":"Nguyen, T. et al. The prevalence of Helicobacter pylori remains high in African American and hispanic veterans. Helicobacter 20 (4), 305\u2013315 (2015).","journal-title":"Helicobacter"},{"issue":"9","key":"84606_CR50","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1038\/s41395-018-0033-8","volume":"113","author":"RJ Wong","year":"2018","unstructured":"Wong, R. J. et al. Race\/ethnicity and insurance status disparities in access to direct acting antivirals for hepatitis C virus treatment. Am. J. Gastroenterol. 113 (9), 1329\u20131338 (2018).","journal-title":"Am. J. Gastroenterol."},{"key":"84606_CR51","doi-asserted-by":"crossref","unstructured":"Binkley, J. M. et al. Racial disparity in breast cancer survivorship: themes from a series of four national healthcare provider live virtual forums. J. Cancer Surviv. 17(4), 1008\u20131016 (2023).","DOI":"10.1007\/s11764-023-01373-6"},{"issue":"1","key":"84606_CR52","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1200\/JCO.2017.74.2049","volume":"36","author":"L Ellis","year":"2018","unstructured":"Ellis, L. et al. Racial and ethnic disparities in Cancer Survival: the contribution of Tumor, Sociodemographic, Institutional, and Neighborhood characteristics. J. Clin. Oncol. 36 (1), 25\u201333 (2018).","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"84606_CR53","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S1470-2045(12)70425-4","volume":"13","author":"Collaborative Group on Hormonal Factors in Breast C","year":"2012","unstructured":"Collaborative Group on Hormonal Factors in Breast C. Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. Lancet Oncol. 13 (11), 1141\u20131151 (2012).","journal-title":"Lancet Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84606-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84606-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84606-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T18:46:31Z","timestamp":1743446791000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84606-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,28]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["84606"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-84606-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,28]]},"assertion":[{"value":"11 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10829"}}